

# Emma Tillman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1446613/publications.pdf>

Version: 2024-02-01

9  
papers

60  
citations

2148532

4  
h-index

1905433

7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

63  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of <i>ADRA2A</i> genotype association with doses of dexmedetomidine for sedation in pediatric patients. <i>Pharmacotherapy</i> , 2022, , .	1.2	1
2	Pharmacogenomics: a tool to improve medication safety and efficacy in patients with cystic fibrosis. <i>Pharmacogenomics</i> , 2022, 23, 559-556.	0.6	1
3	Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Record. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 181-186.	1.0	9
4	UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> , 2021, 13, 1566.	1.7	30
5	Risks and mitigation strategies to prevent etoposide infusion-related reactions in children. <i>Pharmacotherapy</i> , 2021, 41, 700-706.	1.2	5
6	Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in Children. <i>Paediatric Drugs</i> , 2021, 23, 373-380.	1.3	3
7	Methods for Detecting Pediatric Adverse Drug Reactions From the Electronic Medical Record. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1479-1484.	1.0	2
8	Opportunity for pharmacogenomic testing in patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2021, , .	1.0	6
9	Current and future state of clinical pharmacist-led precision medicine initiatives. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 754-764.	0.5	3